These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10779439)

  • 1. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
    Quackenbush RC; Reuther GW; Miller JP; Courtney KD; Pear WS; Pendergast AM
    Blood; 2000 May; 95(9):2913-21. PubMed ID: 10779439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
    Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis.
    Advani AS; Dressman HK; Quiroz M; Taylor GA; Pendergast AM
    Leuk Res; 2004 Mar; 28(3):285-94. PubMed ID: 14687624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.
    Kelliher M; Knott A; McLaughlin J; Witte ON; Rosenberg N
    Mol Cell Biol; 1991 Sep; 11(9):4710-6. PubMed ID: 1875948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL-induced adhesion defects are tyrosine kinase-independent.
    Wertheim JA; Forsythe K; Druker BJ; Hammer D; Boettiger D; Pear WS
    Blood; 2002 Jun; 99(11):4122-30. PubMed ID: 12010816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
    Mandanas RA; Leibowitz DS; Gharehbaghi K; Tauchi T; Burgess GS; Miyazawa K; Jayaram HN; Boswell HS
    Blood; 1993 Sep; 82(6):1838-47. PubMed ID: 7691239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR/ABL induces multiple abnormalities of cytoskeletal function.
    Salgia R; Li JL; Ewaniuk DS; Pear W; Pisick E; Burky SA; Ernst T; Sattler M; Chen LB; Griffin JD
    J Clin Invest; 1997 Jul; 100(1):46-57. PubMed ID: 9202056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML).
    Arana-Trejo RM; Ruíz Sánchez E; Ignacio-Ibarra G; Báez de la Fuente E; Garces O; Gómez Morales E; Castro Granados M; Ovilla Martínez R; Rubio-Borja ME; Solís Anaya L; Herrera P; Delgado Llamas J; Kofman S
    Clin Lab Haematol; 2002 Jun; 24(3):145-50. PubMed ID: 12067277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
    Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
    Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
    Sun X; Layton JE; Elefanty A; Lieschke GJ
    Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate apoptosis response gene-4 (par-4) abrogates the survival function of p185(BCR-ABL) in hematopoietic cells.
    Kukoc-Zivojnov N; Puccetti E; Chow KU; Bergmann M; Ruthardt M; Hoelzer D; Mitrou PS; Weidmann E; Boehrer S
    Exp Hematol; 2004 Jul; 32(7):649-56. PubMed ID: 15246161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABL oncogenes directly stimulate two distinct target cells in bone marrow from 5-fluorouracil-treated mice.
    Kelliher MA; Weckstein DJ; Knott AG; Wortis HH; Rosenberg N
    Oncogene; 1993 May; 8(5):1249-56. PubMed ID: 8479746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.
    Mian AA; Metodieva A; Najajreh Y; Ottmann OG; Mahajna J; Ruthardt M
    Haematologica; 2012 Feb; 97(2):251-7. PubMed ID: 22058195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants.
    Janowska-Wieczorek A; Majka M; Marquez-Curtis L; Wertheim JA; Turner AR; Ratajczak MZ
    Leukemia; 2002 Jun; 16(6):1160-6. PubMed ID: 12040448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector.
    Zhao RC; Jiang Y; Verfaillie CM
    Blood; 2001 Apr; 97(8):2406-12. PubMed ID: 11290604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.